Pfizer Inc. $PFE Shares Bought by Xponance LLC

Xponance LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 8.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 952,256 shares of the biopharmaceutical company’s stock after buying an additional 77,679 shares during the period. Xponance LLC’s holdings in Pfizer were worth $23,711,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in PFE. Horizon Financial Services LLC lifted its stake in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. bought a new stake in Pfizer in the fourth quarter valued at $26,000. YANKCOM Partnership acquired a new position in shares of Pfizer during the fourth quarter valued at $28,000. HFM Investment Advisors LLC increased its holdings in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the period. Finally, Darwin Wealth Management LLC acquired a new position in shares of Pfizer during the second quarter valued at $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a report on Tuesday. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. UBS Group reaffirmed a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Trading Up 2.2%

Shares of NYSE PFE opened at $26.17 on Friday. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The firm has a market capitalization of $149.15 billion, a PE ratio of 19.98 and a beta of 0.34. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The business has a 50-day moving average price of $26.48 and a two-hundred day moving average price of $26.32.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same period last year, the company posted $0.92 EPS. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer said the U.S. FDA expanded the label for HYMPAVZI to include more hemophilia A and B patients, including children ages 6-11 and patients with inhibitors, which could broaden sales potential in a high-value rare disease market. Article Title
• Positive Sentiment: RBC Capital upgraded Pfizer to Sector Perform from Underperform, saying the stock’s valuation has reset and the risk/reward looks more balanced ahead of key pipeline catalysts. Article Title
• Positive Sentiment: Pfizer also highlighted ongoing clinical progress, including updates to trials for its next-gen pneumococcal shot, obesity candidate SOLIS-1, and early-stage research, reinforcing investor hopes that the pipeline can offset future patent and COVID-related revenue pressure. Article Title
• Neutral Sentiment: Several brokerages now rate Pfizer around Hold, suggesting the market sees limited near-term upside until more proof emerges from the pipeline and growth strategy. Article Title
• Negative Sentiment: One article warned that Pfizer’s rich dividend yield may reflect cash-flow and debt concerns, while another noted CEO Albert Bourla is reconsidering Germany investments because of drug-pricing policy risks, both of which could weigh on sentiment. Article Title

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.